AI assistant
Syncona Limited Director's Dealing 2024
6283_mang_2024-03-06_5211f789-b42e-4680-8756-67a2ffc498db.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 8912F
Syncona Limited
06 March 2024
Syncona Limited (the "Company")
Director Declaration
6 March 2024
In accordance with the requirements of the Listing Rule 9.6.14R, the Company advises the following change to directorships in other publicly quoted companies held by the following member of the Board:
Dr Julie Cherrington was appointed to Elevation Oncology, Inc. (Nasdaq: ELEV) on 4 March 2024.
Enquiries
Syncona Ltd
Alasdair Moodie
Tel: +44 (0) 20 3981 7940
Citco Fund Services (Guernsey) Limited
Company Secretary
Tel: +44 (0) 1481 758200
About Syncona:
Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RDNDQLFBZXLLBBB